bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.

Additionally, two oral presentations given by bluebird’s academic collaborators highlighted previously presented data from bluebird bio’s ongoing gene therapy clinical trials. David Williams, M.D., president of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center presented interim data from the Starbeam Study of Lenti-D in cerebral adrenoleukodystrophy, and Marina Cavazzana, M.D., Ph.D., of Hospital Necker, University Paris Descartes, presented interim data from the HGB-205 study of LentiGlobin® in severe sickle cell disease and transfusion-dependent β-thalassemia.

“The preclinical data presented at ASGCT are testament to bluebird’s commitment to developing next-generation immuno-oncology and gene therapies. We are particularly excited about our oncology presentations, which highlighted our progress toward the generation of T cells with sustained anti-tumor activity as well as research on small-molecule regulated multi-chain chimeric antigen receptors known as Darics,” said Philip Gregory, D.Phil., chief scientific officer, bluebird bio. “For our hematopoietic stem cell programs, scalable manufacturing and transduction efficiency remain areas of focus and importance for bluebird. Multiple presentations at ASGCT discussed encouraging examples of our efforts on these fronts – with more to come as we continue to innovate in this critical direction.” (Original Source)

Shares of bluebird bio closed last Friday at $38.52, down $0.18 or -0.47%. BLUE has a 1-year high of $197.35 and a 1-year low of $36.94. The stock’s 50-day moving average is $45.36 and its 200-day moving average is $56.80.

On the ratings front, bluebird has been the subject of a number of recent research reports. In a report issued on May 5, Maxim Group analyst Jason McCarthy reiterated a Buy rating on BLUE, with a price target of $105, which represents a potential upside of 172.6% from where the stock is currently trading. Separately, on the same day, Wells Fargo’s Jim Birchenough reiterated a Buy rating on the stock.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason McCarthy and Jim Birchenough have a total average return of -10.8% and 25.0% respectively. McCarthy has a success rate of 29.5% and is ranked #3695 out of 3828 analysts, while Birchenough has a success rate of 48.0% and is ranked #38.

Overall, 2 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $110.50 which is 186.9% above where the stock closed last Friday.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company develops next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. It has two clinical-stage programs in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease and a preclinical oncology program in the chimeric antigen receptor T cells field. bluebird bio was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.